AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8275152 — intervention group
Group type: COMPARATOR
Intervention: Two-handed compressions
Number of subjects: 108
Study 3437449 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led social influences program
Number of subjects: 0
Study 3437449 — intervention group
Group type: COMPARATOR
Intervention: Health consequences program
Number of subjects: 0
Study 3437449 — intervention group
Group type: COMPARATOR
Intervention: Usual-care comparison group
Number of subjects: 0
Study 31740092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF) + intramuscular Ketorolac
Number of subjects: 220
Study 31740092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (IVF) + intramuscular Ketorolac
Number of subjects: 220
Study 29654308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calcium dialysate (LCD, 1.25 mmol/L Ca2+)
Number of subjects: 174
Study 29654308 — intervention group
Group type: COMPARATOR
Intervention: High-calcium dialysate (HCD, 1.5 mmol/L Ca2+)
Number of subjects: 174
Study 28387538 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured informational and supportive meetings led by a palliative care physician and nurse practitioner.
Number of subjects: 51
Study 25620200 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal‐Abnormal category in the clinical trial cohort
Number of subjects: 93532
Study 25620200 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal‐Abnormal category in the observational study cohort
Number of subjects: 93532
Study 23311688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg every 12 hours
Number of subjects: 104
Study 23311688 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate 200 mg every 12 hours
Number of subjects: 104
Study 21160307 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resection
Number of subjects: 162
Study 21160307 — intervention group
Group type: COMPARATOR
Intervention: Open rectal cancer surgery
Number of subjects: 162
Study 18811636 — intervention group
Group type: EXPERIMENTAL
Intervention: ED consent for telephone follow-up
Number of subjects: 430
Study 18811636 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up without prior ED consent
Number of subjects: 430
Study 18811636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 430
Study 17165495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking therapy (pricking thyroid gland high point)
Number of subjects: 60
Study 17165495 — intervention group
Group type: COMPARATOR
Intervention: Medication (oral administration of tapazole)
Number of subjects: 60
Study 17165495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking therapy
Number of subjects: 60
Study 17165495 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 60
Study 14986593 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (intervention)
Number of subjects: 0
Study 14986593 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study 11031698 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (specific dosage and duration not mentioned)
Number of subjects: 0
Study 11031698 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (lower doses than those used for aggressive tocolysis)
Number of subjects: 0
Study 9382123 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 205
Study 9382123 — intervention group
Group type: COMPARATOR
Intervention: Uninformed consent
Number of subjects: 205
Study 9382123 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed patients
Number of subjects: 205
Study 9382123 — intervention group
Group type: COMPARATOR
Intervention: Uninformed patients
Number of subjects: 205
Study 8282350 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (5, 10, or 20 mg)
Number of subjects: 40
Study 8282350 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (50, 100, or 200 mg)
Number of subjects: 40
Study 2727325 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to think aloud
Number of subjects: 60
Study 2727325 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to recall decision processes
Number of subjects: 60
Study 2727325 — intervention group
Group type: COMPARATOR
Intervention: No instructions to verbalize
Number of subjects: 60
Study 30274540 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol nasal irrigation
Number of subjects: 100
Study 28100212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-adequate breakfast
Number of subjects: 264
Study 28100212 — intervention group
Group type: COMPARATOR
Intervention: Nutrition-inadequate breakfast
Number of subjects: 264
Study 28100212 — intervention group
Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 264
Study 26087670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, 1,000 mg (2 infusions, 14 days apart; repeated at 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Number of subjects: 0
Study 26087670 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CSA), 3.5‐5 mg/kg/day for 6 months (continued for another 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Number of subjects: 0
Study 23399373 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 15
Study 23399373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21098626 — intervention group
Group type: EXPERIMENTAL
Intervention: mF-G score greater than six (hirsutism)
Number of subjects: 1010
Study 21098626 — intervention group
Group type: COMPARATOR
Intervention: mF-G score of zero
Number of subjects: 1010
Study 21098626 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased total testosterone and HbA1(c) levels
Number of subjects: 1010
Study 21098626 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased SHBG levels
Number of subjects: 1010
Study 21098626 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostatic model assessment for insulin resistance
Number of subjects: 1010
Study 19325207 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic extrusive forces
Number of subjects: 26
Study 19325207 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic intrusive forces
Number of subjects: 26
Study 19325207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 17446337 — intervention group
Group type: EXPERIMENTAL
Intervention: Denufosol tetrasodium (20, 40, or 60 mg) administered three times daily for 28 days
Number of subjects: 89
Study 17446337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) administered three times daily for 28 days
Number of subjects: 89
Study 14742349 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective or fluorescent clothing
Number of subjects: 463
Study 14742349 — intervention group
Group type: EXPERIMENTAL
Intervention: White helmet
Number of subjects: 463
Study 14742349 — intervention group
Group type: EXPERIMENTAL
Intervention: Light coloured helmet
Number of subjects: 463
Study 14742349 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime headlight operation
Number of subjects: 463
Study 14742349 — intervention group
Group type: COMPARATOR
Intervention: No reflective or fluorescent clothing
Number of subjects: 463
Study 14742349 — intervention group
Group type: COMPARATOR
Intervention: Non-white helmet
Number of subjects: 463
Study 14742349 — intervention group
Group type: COMPARATOR
Intervention: Dark coloured helmet
Number of subjects: 463
Study 14742349 — intervention group
Group type: COMPARATOR
Intervention: No daytime headlight operation
Number of subjects: 463
Study 11214054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 60
Study 11214054 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 60
Study 9677789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg e.v. every six hours
Number of subjects: 70
Study 9677789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7673950 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Number of subjects: 6
Study 7673950 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study 2405864 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy (median dose 7.5 mg/week)
Number of subjects: 32
Study 2405864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) during low-dose methotrexate (MTX) therapy
Number of subjects: 32
Study 2405864 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy
Number of subjects: 32
Study 2405864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study 7431608 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent pneumococcal vaccine (Pneumovax) at baseline followed by saline placebo four weeks later.
Number of subjects: 50
Study 7431608 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline followed by polyvalent pneumococcal vaccine (Pneumovax).
Number of subjects: 50
Study 7431608 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 volunteers) receiving polyvalent pneumococcal vaccine (Pneumovax).
Number of subjects: 50
Study 7431608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (diabetics and controls) receiving the vaccine.
Number of subjects: 50
Study 7431608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (diabetics and controls).
Number of subjects: 50
Study 31675664 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day for 6 weeks)
Number of subjects: 49
Study 31675664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28455382 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 2474
Study 24571538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (preschool-based intervention to reduce screen time)
Number of subjects: 0
Study 24571538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 24571538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 23046599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) as induction therapy and thereafter as monthly infusions for 26 weeks
Number of subjects: 62
Study 23046599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 23046599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 62
Study 23046599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) during induction therapy
Number of subjects: 62
Study 23046599 — intervention group
Group type: COMPARATOR
Intervention: Placebo during maintenance therapy
Number of subjects: 62
Study 20730514 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for 1 year
Number of subjects: 16
Study 20730514 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched subjects)
Number of subjects: 16
Study 19430807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence of 80 rpm at 60% W (max)
Number of subjects: 18
Study 19430807 — intervention group
Group type: COMPARATOR
Intervention: Cadence of 50 rpm
Number of subjects: 18
Study 19430807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence of 50, 65, 80, 95, and 110 rpm
Number of subjects: 18
Study 19430807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence of 80 rpm
Number of subjects: 18
Study 16858182 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin (400 mg q24 hours)
Number of subjects: 656
Study 16858182 — intervention group
Group type: COMPARATOR
Intervention: IV piperacillin-tazobactam (3.0/0.375 g q6 hours) +/− PO amoxicillin-clavulanate (800 mg/114 mg q12 hours)
Number of subjects: 656
Study 16858182 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin
Number of subjects: 656
Study 16858182 — intervention group
Group type: COMPARATOR
Intervention: IV piperacillin-tazobactam +/− PO amoxicillin-clavulanate
Number of subjects: 656
Study 12482564 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin for 4 weeks after coronary stent placement
Number of subjects: 1010
Study 12482564 — intervention group
Group type: COMPARATOR
Intervention: placebo for 4 weeks after coronary stent placement
Number of subjects: 1010
Study 12482564 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae‐specific IgG antibody levels
Number of subjects: 1010
Study 12482564 — intervention group
Group type: EXPERIMENTAL
Intervention: stratification by antibody levels
Number of subjects: 1010
Study 10869578 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual counting task
Number of subjects: 49
Study 10869578 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuoperceptual tasks (identification of overlapping figures and discrimination of visual forms)
Number of subjects: 49
Study 1869801 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin containing oral rehydration salts (ORS) solution
Number of subjects: 69
Study 1869801 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended glucose‐ORS solution
Number of subjects: 69
Study 6222704 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5% lotion) applied twice daily for four weeks
Number of subjects: 9
Study 6222704 — intervention group
Group type: COMPARATOR
Intervention: Hexachlorophene (3% colloidal suspension) applied twice daily for four weeks
Number of subjects: 9
Study 30669704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein-high fat diet (LP-HF)
Number of subjects: 12
Study 30669704 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein-low fat diet (HP-LF)
Number of subjects: 12
Study 28643570 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic instrumental music performance, 12 individual clinical contacts, twice weekly for six weeks.
Number of subjects: 11
Study 28643570 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic instrumental music performance
Number of subjects: 11
Study 27994711 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC ECC system (Group I)
Number of subjects: 32
Study 27994711 — intervention group
Group type: COMPARATOR
Intervention: Noncoated ECC system (Group II)
Number of subjects: 32
Study 25016604 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Motivation Inventory (PMI)
Number of subjects: 42
Study 22068638 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR spectroscopy added to traditional morphological evaluation
Number of subjects: 327
Study 22068638 — intervention group
Group type: COMPARATOR
Intervention: Traditional morphological evaluation only
Number of subjects: 327
Study 20543740 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-pronated grip
Number of subjects: 12
Study 20543740 — intervention group
Group type: COMPARATOR
Intervention: Wide-supinated grip
Number of subjects: 12
Study 20543740 — intervention group
Group type: COMPARATOR
Intervention: Narrow-pronated grip
Number of subjects: 12
Study 20543740 — intervention group
Group type: COMPARATOR
Intervention: Narrow-supinated grip
Number of subjects: 12
Study 18626566 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1‐84)
Number of subjects: 90
Study 18626566 — intervention group
Group type: COMPARATOR
Intervention: HT alone
Number of subjects: 90
Study 18626566 — intervention group
Group type: EXPERIMENTAL
Intervention: HT + PTH(1‐84)
Number of subjects: 90
Study 15921383 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally adapted guidelines (GL) for VTE prophylaxis
Number of subjects: 500
Study 12638327 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM-R
Number of subjects: 29
Study 12638327 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM-NR
Number of subjects: 29
Study 12638327 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 29
Study 11561568 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 300 mg daily for 10 days
Number of subjects: 104
Study 11561568 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 600 mg daily for 10 days
Number of subjects: 104
Study 7486929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 6
Study 7486929 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 6
Study 2142580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (30 micrograms) combined with gestodene (75 micrograms)
Number of subjects: 60
Study 2142580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (30 micrograms) combined with desogestrel (150 micrograms)
Number of subjects: 60
Study 6197010 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Number of subjects: 70
Study 6197010 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 injection (Control)
Number of subjects: 70
Study 6197010 — intervention group
Group type: COMPARATOR
Intervention: Well-nourished children (Control)
Number of subjects: 70
Study 30892564 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided app-based VR CBT (n = 96)
Number of subjects: 193
Study 30892564 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 97)
Number of subjects: 193
Study 29536296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal paclitaxel (60 mg/m2 on days 0, 14, 21, 28, 42, 49, and 56)
Number of subjects: 83
Study 29536296 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel (80 mg/m2 on the same schedule)
Number of subjects: 83
Study 26872608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 145
Study 26872608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 25260232 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Qur™ Film
Number of subjects: 84
Study 25260232 — intervention group
Group type: COMPARATOR
Intervention: Control (no adhesion barrier)
Number of subjects: 84
Study 23968742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and activity education+behavioral intervention
Number of subjects: 21
Study 23968742 — intervention group
Group type: COMPARATOR
Intervention: Nutrition and activity education
Number of subjects: 21
Study 20959311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 416
Study 20959311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 416
Study 17908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersive-viscoadaptive soft-shell technique using Viscoat and Healon 5 (V-group)
Number of subjects: 171
Study 17908256 — intervention group
Group type: COMPARATOR
Intervention: Dispersive-cohesive soft-shell technique with Viscoat and Opegan-Hi (C-group)
Number of subjects: 171
Study 17908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersive-viscoadaptive soft-shell technique (V-group) with ultrasound of 10 %Min or less
Number of subjects: 171
Study 17908256 — intervention group
Group type: COMPARATOR
Intervention: Dispersive-cohesive soft-shell technique (C-group) with ultrasound of 10 %Min or less
Number of subjects: 171
Study 17908256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersive-viscoadaptive soft-shell technique (V-group) with ultrasound of over 10 %Min
Number of subjects: 171
Study 17908256 — intervention group
Group type: COMPARATOR
Intervention: Dispersive-cohesive soft-shell technique (C-group) with ultrasound of over 10 %Min
Number of subjects: 171
Study 16055155 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at the left dorsolateral prefrontal cortex (DLPFC) (40 trains of 2 s duration, 20 Hz stimuli)
Number of subjects: 0
Study 16055155 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 0
Study 12627499 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 370
Study 12627499 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast radiation
Number of subjects: 370
Study 12627499 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 370
Study 10371789 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. procainamide
Number of subjects: 136
Study 10371789 — intervention group
Group type: COMPARATOR
Intervention: DC shock
Number of subjects: 136
Study 10371789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 136
Study 10371789 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial size
Number of subjects: 136
Study 8791972 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 12
Study 1869405 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 2% drops administered twice a day for 2 weeks
Number of subjects: 18
Study 1869405 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice a day for 2 weeks
Number of subjects: 18
Study 7065469 — intervention group
Group type: EXPERIMENTAL
Intervention: lodoxamide ethyl
Number of subjects: 10
Study 7065469 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct measurement of area by planimetry
Number of subjects: 10
Study 30609202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 9
Study 30239552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-β-carotene tomato juice (30.4 mg of β-carotene)
Number of subjects: 35
Study 30239552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lycopene tomato juice (42.5 mg of lycopene)
Number of subjects: 35
Study 30239552 — intervention group
Group type: COMPARATOR
Intervention: Carotenoid-free control (cucumber juice)
Number of subjects: 35
Study 27405054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus feeding (BF)
Number of subjects: 10
Study 27405054 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion feeding (SF)
Number of subjects: 10
Study 24467807 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect Regulation Training
Number of subjects: 120
Study 24467807 — intervention group
Group type: COMPARATOR
Intervention: Active common factor based treatment
Number of subjects: 120
Study 24467807 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 120